AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 82 min read$MDT

Medtronic (MDT) Q1 2027 Earnings Call Transcript

Medtronic (MDT) reported Q1 2027 revenue of $9.8B, up 13.7% YoY, and adjusted EPS of $1.45, exceeding expectations. Strong growth was seen in CRM, CST, and Surgical segments. Cardiac Ablation Solutions grew 88% worldwide, and Symplicity showed progress. The company remains confident in its fiscal '27 targets and long-term growth trajectory.

Original reporting
yahoo.com
Published Sep 8, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medtronic (MDT) Q1 2027 Earnings Call Transcript — source image
Source · yahoo.com
Decision brief

The 30-second read

$MDTBullishHigh
01

Why it matters

The earnings beat reinforces Medtronic's growth narrative and may lift related medical device stocks.

02

Market read

Large‑cap MedTech earnings beat can drive sector‑wide buying pressure.

03

What to watch

Guidance for FY27 was not disclosed; future guidance could temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: post‑market release

Background

Medtronic's Q1 FY27 earnings call provides the first public disclosure of quarterly results.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Q1 FY27 earnings released with $9.8B revenue and $1.45 adjusted EPS, beating expectations.

Expected impact

Potential short‑term price rally on earnings beat.

Evidence & confidence

Large‑cap earnings beat with clear guidance often drives immediate buying pressure.

Market effects

Sector

MedTech sector may see broader optimism as a leading player reports strong growth.

Regional

U.S. healthcare stocks could benefit from the earnings beat.

Global

International MedTech peers may be re‑rated higher on the back of MDT's performance.

Counterpoint

What could challenge this read

If the market has already priced in the beat, the upside may be limited.

Key entities

  • Company
    Medtronic

    Global medical device manufacturer reporting FY27 Q1 results.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 9
$MDTHighAI 8/10

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic (MDT) raised its 2027 outlook after Q1 earnings and revenue beat expectations, with adjusted EPS at $1.45 (+15.1% YoY) and revenue at $9.76B (+13.7% YoY). The company increased revenue and EPS guidance, citing strong performance across major businesses. Acquisitions in neurovascular and pain therapies are expected to contribute over $150M in revenue for 2027.

finance.yahoo.com2 min
SEP 9
$MDTMed

Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be

Medtronic (MDT) has undergone strategic shifts, exiting less profitable businesses and investing in new technology, leading to its highest annual revenue growth in a decade. Q1 fiscal 2027 saw a 13.7% revenue increase and earnings above guidance, prompting raised full-year forecasts. The stock has risen 15% in three months but remains 30% below its 2021 high, offering a high dividend yield.

fool.com2 min
SEP 8
$MDTMedAI 8/10

Down Stocks to Buy and Hold for the Next 10 Years

Medtronic (MDT) reported Q1 2027 revenue of $9.8B, up 13.7% YoY, and raised full-year guidance. Despite a 2% YTD decline, its long-term growth prospects and dividend history make it attractive. MercadoLibre (MELI) saw Q2 revenue rise 50% YoY to $10.2B but EPS fell due to investments. Its initiatives aim to strengthen its market position and moat.

aol.com3 min